KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $142.6 million.

  • Nektar Therapeutics' Cash from Investing Activities fell 305.73% to -$94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.6 million, marking a year-over-year decrease of 41.20%. This contributed to the annual value of $142.6 million for FY2024, which is 2.15% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Cash from Investing Activities of $142.6 million as of FY2024, which was up 2.15% from $139.6 million recorded in FY2023.
  • Nektar Therapeutics' 5-year Cash from Investing Activities high stood at $496.2 million for FY2020, and its period low was $139.6 million during FY2023.
  • Over the past 3 years, Nektar Therapeutics' median Cash from Investing Activities value was $142.6 million (recorded in 2024), while the average stood at $216.0 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 139.85% in 2020, then crashed by 61.85% in 2023.
  • Over the past 5 years, Nektar Therapeutics' Cash from Investing Activities (Yearly) stood at $496.2 million in 2020, then tumbled by 59.14% to $202.8 million in 2021, then surged by 80.41% to $365.8 million in 2022, then slumped by 61.85% to $139.6 million in 2023, then increased by 2.15% to $142.6 million in 2024.